3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
A comprehensive review of bremelanotide (Vyleesi) adverse event rates from Phase II/III trials, FDA labeling, FAERS data, and post-market literature, with real incidence figures and clinical context.
A clinically detailed review of bremelanotide (Vyleesi) adverse events, discontinuation data from Phase 3 trials, FAERS reports, and post-market literature, including whether a true withdrawal syndrome exists.
A clinical deep-dive into the rare but serious adverse events of bremelanotide (Vyleesi), including transient hypertension, focal hyperpigmentation, nausea, and post-market FAERS signals. prepared by the HealthRX.com Editorial Team.